{"filings":[{"id":1203599,"accession_number":"0001193125-26-278068","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-06-23T00:22:28+00:00","items":["5.07"],"status":"ready","headline":"Tempest Therapeutics shareholders approve stock issuance for warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 passed: 9,090,763 votes for issuance of up to 925,927 shares from Series A and B warrants (March 2026 private placement).","Proposal 2 passed: 9,091,165 votes for issuance of up to 2,344,828 shares from Common Warrants (November 2025 inducement).","Both proposals had ~9.09M for, ~398k against, ~18k abstentions at the June 18, 2026 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863078,"accession_number":"0001193125-26-257684","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-06-04T21:00:25+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.","Board appoints Drake Richey and John Yee, MD, MPH as Class II independent directors effective June 4, 2026.","Company received Nasdaq non-compliance notice on May 22 due to board vacancies; believes it can cure with one remaining vacancy.","Amended director compensation policy reduces annual cash retainers: base $20K, committee chair $5K-$10K, member $2.5K-$5K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787013,"accession_number":"0001193125-26-251994","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-06-01T23:13:20+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises 1,172,414 existing warrants at reduced $1.73/share for ~$2M cash gross proceeds.","Company issues new warrant for up to 2,344,828 shares at $1.73, exercisable after stockholder approval, expiring May 29, 2028.","Placement agent H.C. Wainwright receives warrants for 82,069 shares at $2.1625 per share.","Company to file resale registration statement within 30 days; use best efforts to effect within 45 or 75 days.","Existing warrants originally issued in November 2025 at $3.50 exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748677,"accession_number":"0001193125-26-248648","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-29T21:01:10+00:00","items":["5.02"],"status":"ready","headline":"Tempest Therapeutics director Simantov resigns from Board effective May 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Simantov resigned from the Board; no disagreement with company operations or policies.","Separation Agreement waives all accrued and unpaid retainer fees from director compensation program.","Her outstanding stock option awards and share ownership are unaffected; indemnification agreement continues for six years.","Full text of Separation Agreement will be filed with the Company's Q2 2026 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":612080,"accession_number":"0001193125-26-237207","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-22T21:28:16+00:00","items":["3.01","5.02"],"status":"ready","headline":"Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.","Directors Michael Raab and Christine Pellizzari resigned, causing non-compliance with majority independence and committee rules.","Company not eligible for standard cure period due to multiple vacancies; must submit plan for board compliance within 45 days.","Both deficiencies have no immediate listing effect but risk delisting if plans rejected or compliance not achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611637,"accession_number":"0001193125-26-237150","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-22T21:05:53+00:00","items":["5.02"],"status":"ready","headline":"Three directors resign from Tempest Therapeutics board effective May 22, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Brady, Michael Raab, and Christine Pellizzari resigned from the Tempest board on May 22, 2026.","Resignations not due to any disagreement with the company on operations, policies, or practices.","Separation agreements waive accrued unpaid director retainer fees; stock options and indemnification remain.","Board size reduced by three members; no replacements announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443443,"accession_number":"0001193125-26-224156","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-14T20:28:56+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.","TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.","Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.","Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.","Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93558,"accession_number":"0001193125-26-207601","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.","Favorable safety: no Grade >3 CRS or ICANS observed; 44 patients dosed across three studies to date.","Median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease.","All 10 evaluable REDEEM-1 patients achieved CR per IMWG criteria; one prior BCMA CAR-T patient did not respond.","Company plans to meet with FDA later this year to discuss initiating a U.S. registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105281,"accession_number":"0001193125-26-130480","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.","Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.","Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.","TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.","Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105280,"accession_number":"0001193125-26-118618","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tempest Therapeutics raises ~$2M in private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$2M gross from private placement of 462,964 shares + pre-funded warrants at $2.16 per unit.","Issued Series A (5-yr) and Series B (24-mo) warrants exercisable at $2.16; exercisable upon stockholder approval.","Proceeds to be used for working capital; closing expected March 23, 2026.","Registration rights agreement requires filing resale registration within 15 days.","H.C. Wainwright served as placement agent; fees of 6% (institutional) and 3% (strategic)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105279,"accession_number":"0001193125-26-068614","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.","Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.","Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.","Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.","Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105278,"accession_number":"0001193125-26-045543","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tempest Therapeutics files updated corporate presentation; no specific new data disclosed in filing.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted February 2026 investor presentation on its website.","Presentation title: 'Accelerating the Development of Advanced Therapies for Cancer Patients'.","No financial or clinical trial results were included in the 8-K filing.","Investors should refer to the full presentation on the company's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105277,"accession_number":"0001193125-26-041190","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","2.01","3.02","5.01","5.02","9.01"],"status":"ready","headline":"Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.","Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.","Geoff Nichol resigned from Board; Michael Raab stepped down as Chair; Stephen Brady appointed Chair.","Stephen Brady resigned as CEO; Matt Angel appointed President, CEO and Class I director; $650k salary, 50% bonus, 269,621 option.","Issued 6.78M warrants at $18.48/exercise, expiring Feb 3 2031, to existing shareholders as a dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105276,"accession_number":"0001193125-26-027203","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["3.03","5.02","5.07"],"status":"ready","headline":"Tempest shareholders approve share issuance for asset purchase and extend rights plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.","Stockholders extended limited duration rights plan to October 10, 2026.","Amendment to 2023 Equity Incentive Plan approved, increasing share reserve by 1,410,000 shares.","Geoff Nichol elected Class I director with 1,003,845 votes for; broker non-votes 1,075,928.","Advisory say-on-pay approved with 816,856 votes for, 428,524 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105275,"accession_number":"0001193125-26-008938","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tempest Therapeutics gets Nasdaq notice for missing annual meeting; meeting set for Jan 27, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Jan 8, 2026 for failing to hold annual meeting within 12 months of fiscal year end Dec 31, 2024.","Company has 45 calendar days (until Feb 23, 2026) to regain compliance or submit a plan; Nasdaq may grant exception until June 29, 2026.","Annual meeting already scheduled for Jan 27, 2026; upon holding it, compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121542,"accession_number":"0001193125-25-298604","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Tempest raises $4.25M upfront in registered direct offering; warrants add up to $4.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,172,414 shares (or equivalents) sold at $3.625/share in registered direct offering for ~$4.25M gross.","Concurrent private placement of short-term warrants to buy 1,172,414 shares at $3.50, exercisable for 18 months.","Warrants could yield additional ~$4.1M proceeds if fully exercised on a cash basis, but no guarantee.","Net proceeds used for working capital and general corporate purposes; H.C. Wainwright placement agent with 6% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121541,"accession_number":"0001193125-25-287163","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.","Post-closing, existing TPST holders own ~35%; Erigen equityholders (Matt Angel and Lotus Capital) own ~38% and ~27% on fully diluted basis.","Matt Angel appointed President & CEO; Stephen Brady becomes Chairman; Geoff Nichol resigns from board, effective at closing.","Each TPST share to receive one warrant exercisable at $18.48 per share, valid for 5 years from issue date.","Closing requires stockholder approval, Angel's appointment, and a minimum $5M pre-closing financing; expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121540,"accession_number":"0001193125-25-265937","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.","Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.","R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.","Company continues strategic alternatives process to maximize stockholder value.","Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138211,"accession_number":"0000950170-25-106544","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.","Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.","R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.","Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.","Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155656,"accession_number":"0001193125-25-139899","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Tempest Therapeutics raises ~$4.6M gross in registered direct offering of stock and prefunded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 405,000 shares at $6.25 each and prefunded warrants for 334,000 shares at $6.249 each.","Net proceeds estimated at ~$4.1M after placement agent fees and expenses.","Proceeds to support strategic alternative process and working capital; cash runway into Q2 2026.","Placement agent H.C. Wainwright receives 6.0% cash fee on gross proceeds.","Prefunded warrants exercisable at $0.001 per share, with 4.99% beneficial ownership limitation (holder may elect up to 9.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155655,"accession_number":"0001193125-25-138802","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest Therapeutics suspends ATM prospectus; Sales Agreement remains in effect","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered notice to Jefferies to terminate ATM prospectus dated Feb 6, 2025.","No sales of common stock under Sales Agreement until new prospectus filed.","Underlying Open Market Sale Agreement with Jefferies remains in full force.","Company retains ability to resume ATM sales after filing new prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155654,"accession_number":"0001193125-25-137041","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.","Consulting agreements are one-year, hourly compensation; executives retain their roles and responsibilities.","Separation agreements provide full acceleration of all outstanding equity awards, vested immediately on June 5, 2025.","Extended post-Transition exercise period to earlier of Change of Control or 180 days after separation.","Transition part of previously announced process to explore strategic alternatives and extend capital resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155653,"accession_number":"0000950170-25-070416","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.","Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.","Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.","FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.","TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155652,"accession_number":"0001193125-25-098817","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).","Rule requires minimum bid price of $1.00 per share for continued listing.","Company had previously been notified of deficiency; now resolved.","No other regulatory or operational updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155651,"accession_number":"0001193125-25-085773","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.","Estimated $1.5M in cash severance and benefit costs, mostly in Q2 2025.","Key affected employees to transition to consulting agreements.","Company initiated process to explore strategic alternatives to extend capital resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155650,"accession_number":"0001193125-25-076938","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.","Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.","Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.","TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.","Company cites unavailable capital markets as reason to seek a strategic partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155649,"accession_number":"0001193125-25-073987","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Tempest Therapeutics announces 1-for-13 reverse stock split effective April 8, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:13 ratio, effective 5:00 p.m. ET on April 8, 2025.","Pre-split shares outstanding: 45,764,184; post-split approx. 3,520,321 shares.","No fractional shares; cash payments in lieu of fractional shares.","Trading on Nasdaq Capital Market on split-adjusted basis from April 9, 2025.","Proportional adjustments to warrants/options exercise prices and shares reserved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174141,"accession_number":"0000950170-25-046055","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.","Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.","Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.","Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.","FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191092,"accession_number":"0001193125-24-287170","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tempest Therapeutics receives Nasdaq bid price deficiency notice; stock below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Dec 27, 2024 for bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days (until June 25, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.","Stockholders approved a reverse stock split (range 1:2 to 1:15) on Dec 3, 2024; Board may implement to cure deficiency.","If not compliant by June 25, 2025, may qualify for an additional 180-day period if other listing standards are met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191091,"accession_number":"0001193125-24-272464","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","3.03","5.07","9.01"],"status":"ready","headline":"Tempest Therapeutics stockholders approve reverse stock split proposal at ratios up to 1-for-15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split proposal at special meeting on December 3, 2024.","Ratio range: 1-for-2 to 1-for-15, inclusive, with board to set final ratio in its discretion.","Vote results: 12,723,707 for, 9,810,591 against, 415,687 abstentions.","On December 5, 2024, entered Amendment No. 2 to Rights Agreement for technical board administration changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191090,"accession_number":"0000950170-24-125444","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest reports Q3 net loss $10.6M; gets FDA go-ahead for amezalpat Phase 3 in first-line HCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M ($0.41/sh) in Q3 2024 vs $6.8M ($0.48) in Q3 2023; cash $22.1M, then raised $19.9M net via ATM.","FDA issued 'Study May Proceed' letter for pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in first-line HCC.","Announced agreement with Roche to supply atezolizumab globally for the Phase 3 trial; Tempest retains all rights to amezalpat.","Positive end-of-Phase 2 FDA meeting: agreement on Phase 3 design, dose, statistical plan with early efficacy analysis.","Expanded leadership: Troy M. Wagner as VP Quality Assurance and Sheldon Mullins as VP Regulatory Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191089,"accession_number":"0001193125-24-235598","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.","Phase 3 study: TPST-1120 + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab; Tempest retains all data from the trial.","Board extended rights plan to expire after 2025 annual meeting or Oct 2026 if stockholders approve, citing stock undervaluation after positive survival data and FDA alignment.","Rights plan triggers at 10% beneficial ownership (15% for passive institutions), with grandfathering for existing holders above threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207561,"accession_number":"0000950170-24-094102","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.","Company plans to advance amezalpat into a registrational Phase 3 study in first-line HCC.","TPST-1495 to enter Phase 2 in Familial Adenomatous Polyposis in 2024 under NCI funding.","Q2 2024 net loss $9.6M ($0.42 per share); cash and equivalents $31.1M as of June 30, 2024.","R&D expenses $5.8M in Q2 2024 vs $4.4M in Q2 2023, increase due to CRO costs and stock compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225003,"accession_number":"0001193125-24-164015","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.","Hazard ratio of 0.65 for OS, stable from 0.59 at primary analysis 10 months earlier.","20/40 amezalpat patients remain in survival follow-up vs 9/30 control.","Entered new Open Market Sale Agreement to sell up to $205M of common stock.","Tempest retains all product rights; data supports potential pivotal Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225002,"accession_number":"0001193125-24-161685","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tempest Therapeutics announces 2024 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Stephen Brady, Michael Raab, and Ronit Simantov as Class III directors for three-year terms.","Advisory vote on named executive officer compensation passed with 7,466,910 for, 167,307 against, 275,440 abstentions.","Ratification of Ernst & Young as independent auditor for FY2024 approved with 14,040,756 for, 132,300 against, 21,465 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225001,"accession_number":"0000950170-24-057047","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $32.3M at March 31, 2024; expects runway into Q2 2025.","Net loss $7.9M ($0.36/sh) vs $7.6M ($0.55/sh) YoY; R&D $4.3M, G&A $3.6M.","TPST-1120 plans to advance to pivotal Phase 3 in first-line HCC, subject to FDA feedback.","TPST-1495 planned for Phase 2 in FAP in 2024 under NCI funding; updated data expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244243,"accession_number":"0000950170-24-033464","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.","TPST-1120 triplet arm: 30% cORR vs 13.3% control; OS HR 0.59 favoring TPST-1120 in first-line HCC.","Plan to advance TPST-1120 into pivotal Phase 3 in HCC; TPST-1495 into Phase 2 FAP (pending NCI).","R&D expenses down to $17.5M from $22.5M, primarily due to lower CRO costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261659,"accession_number":"0000950170-23-061271","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.","Cash $11.1M at Sep 30; after $23.9M ATM net proceeds, preliminary cash $32.8M extending runway into 2025.","TPST-1120 triplet arm cORR 30% vs 13.3% control; median PFS 7 mo vs 4.27 mo (HR 0.7); median OS not reached vs 15.1 mo (HR 0.59).","Plan to advance TPST-1120 into registrational study in first-line HCC, likely with a partner.","Adopted limited-duration stockholder rights plan on Oct 10, 2023 to deter hostile accumulation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261658,"accession_number":"0001193125-23-265621","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal Nasdaq notification on Oct 26, 2023, confirming compliance with Listing Rule 5450(a)(1).","Rule requires closing bid price of at least $1.00 per share for continued listing.","Regaining compliance removes potential delisting risk for TPST common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261657,"accession_number":"0001193125-23-253882","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.","PFS HR 0.7 (median 7 mo vs 4.27 mo); OS HR 0.59 (median not reached vs 15.1 mo).","In beta-catenin mutation patients, cORR 43% and DCR 100%; in PD-L1 negative, cORR 27% vs 7% control.","Adopted limited duration rights plan; triggers at 10% (15% passive); expires Oct 2024 or 2026 if approved.","40% of TPST-1120 arm patients remain on treatment vs 16.7% control; safety comparable between arms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278879,"accession_number":"0001193125-23-231557","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tempest Therapeutics receives Nasdaq bid price deficiency notice, 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified TPST on Sept 6, 2023 that bid price closed below $1.00 for 30 consecutive days.","Company has 180 calendar days, until March 4, 2024, to regain compliance.","To comply, closing bid must be at least $1.00 for a minimum of ten consecutive business days.","If not compliant by March 4, 2024, TPST may seek an additional 180-day period if eligible.","Company states it will monitor bid price and evaluate options, including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278878,"accession_number":"0001193125-23-230659","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.","Resignation not due to any disagreement with Tempest on operations, policies, or practices.","CEO Stephen Brady will be appointed as president and CEO effective Sep 15, 2023; his responsibilities unchanged.","Dubensky expected to enter consulting agreement: $8,000 retainer for initial period (Sep 15–Oct 15), then $500/hour for services.","Consulting period expected until at least Dec 15, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278877,"accession_number":"0000950170-23-041385","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.","Net loss Q2 2023 $7.6M ($0.54/share) vs $9.2M ($0.79/share) in Q2 2022.","TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% (5/29) for control; confirmed ORR 17.5% vs 10.3%.","47.5% of TPST-1120 arm patients on treatment vs 23.3% in control; 80% on study vs 50%.","Expect to discuss updated TPST-1120 data from formal review in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297148,"accession_number":"0001193125-23-169021","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.","Re-elected Thomas Dubensky and Christine Pellizzari as Class II directors to serve until 2026.","Advisory vote on executive compensation approved with 7,355,907 votes for, 55,375 against.","Ratified Ernst & Young as independent registered public accounting firm for fiscal 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297147,"accession_number":"0000950170-23-020569","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.","TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% control, 74.4% relative improvement.","Confirmed ORR 17.5% (7/40) vs 10.3% control, 69.9% relative improvement; 80% TPST-1120 arm on study vs 50% control.","TPST-1495 enrolling endometrial cancer arm with pembrolizumab; TREX1 inhibitor preclinical data presented at AACR.","Expects updated TPST-1120 data from Roche; plans to report TPST-1495 data at ASCO 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297146,"accession_number":"0001193125-23-124510","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.","Confirmed ORR 17.5% (7/40) vs 10.3% (3/29) control, a 69.9% relative improvement.","47.5% (19/40) of TPST-1120 arm patients remain on treatment vs 23.3% (7/30) in control arm.","80% (32/40) in TPST-1120 arm on study vs 50% (15/30) control; safety consistent with control.","Secondary endpoints (DoR, PFS, OS) immature; full data expected at a medical meeting later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317525,"accession_number":"0001193125-23-088320","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest Therapeutics reports preliminary approval of OvaScience derivative settlement","summary_kind":"llm","event_type":"litigation","confidence":"medium","bullets":["Cima v. Dipp derivative lawsuit settlement received preliminary court approval on March 23, 2023.","Upon final approval of the Cima settlement, a motion to dismiss the related Chiu v. Dipp action will be filed.","Settlement involves claims against OvaScience (predecessor) and former officers for alleged breach of fiduciary duties.","Settlement terms are described in a notice available on Tempest's investor website.","Litigation stems from OvaScience's January 2015 follow-on public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317524,"accession_number":"0000950170-23-009236","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.","Net loss $35.7M vs $28.3M in 2021; R&D expenses $22.5M (+31% YoY).","TPST-1120 Phase 1 showed 30% ORR at highest doses in checkpoint-inhibitor non-responsive patients.","Randomized Phase 1b/2 study in first-line HCC fully enrolled; initial data expected H1 2023.","TPST-1495 Phase 1 dose escalation ongoing; initial data expected by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335756,"accession_number":"0001193125-22-314745","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Tempest Therapeutics Amends Loan Agreement with Oxford Finance, Adds Borrowers and Extends Interest-Only Period","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tempest Therapeutics entered into a First Amendment to Loan and Security Agreement with Oxford Finance LLC on Dec 23, 2022.","The amendment adds Tempest Therapeutics and Millendo Therapeutics US as co-borrowers under the loan.","Interest-only repayment period extended through Dec 31, 2023, with possible extension to June 30, 2024.","Lender permitted a one-time prepayment of $5.0 million by Dec 28, 2022.","Minimum liquidity covenant of $5.0 million in collateral accounts required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335755,"accession_number":"0001544227-22-000004","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q3 2022 net loss $8.9M; cash at $42.8M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $42.8M as of Sep 30, 2022, down from $51.8M at Dec 31, 2021.","Net loss Q3 2022 of $8.9M ($0.66/sh) vs $8.1M ($1.21/sh) in Q3 2021.","R&D expense increased to $6.0M from $4.6M on expanded R&D efforts.","TPST-1120 Phase 1b/2 HCC study with Roche; early data from first 40 patients expected H1 2023.","TPST-1495 Phase 1 dose optimization data expected by year-end or early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26060315.083798885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-08T23:59:59+00:00|335755"}